Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation

Blood

Volumn 93, Issue 5, 1999, Pages 1643-1650

  Belkov, Vladimir M ^b   Eugene, Y ^b   Schuetz, John D ^b   Yanishevski, Yuri ^b   Masson, Eric ^b   Mathew, Susan ^b   Raimondi, Susana ^b   Ching Hon, Pui ^b   Relling, Mary V ^b   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; MESSENGER RNA; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL LINEAGE; CHROMOSOME 21; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PLOIDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0345291171     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.5.1643.405k06_1643_1650     Document Type: Article

References (31)

1. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J: Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907, 1985
2. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR: Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041, 1996
3. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, Crist WM, Pui CH, Evans WE: Blast cell methotrexatepolyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996, 1994
4. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, Beaulieu D: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 76:44, 1990
5. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA: The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094, 1983
6. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, Priest DG, Evans WE: Differences in constitutive and post-methotrexate folylpoly-glutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84:564, 1994
7. Raimondi SC, Pui CH, Hancock ML, Behm FG, Filatov L, Rivera GK: Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 10:213, 1996
8. Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, Meltzer PS, Cowan KH: Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transportdeficient, methotrexate-resistant human breast cancer cells. Cancer Res 55:3790, 1995
9. Pui CH, Crist WM, Look AT: Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76:1449, 1990
10. Wong SC, Proefke SA, Bhushan A, Matherly LH: Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 270:17468, 1995
11. Matherly LH, Angeles SM, Czajkowski CA: Characterization of transport-mediated methotrexate resistance in human tumor cells with antibodies to the membrane carrier for methotrexate and tetrahydrofolate cofactors. J Biol Chem 267:23253, 1992
12. Romanini A, Chou TC, Bertino JR: Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-CEM cell lines sensitive and resistant to methotrexate. Adv Enzyme Regul 28:323, 1989
13. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR: Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89:1013, 1997
14. Scheuermann RH, Bauer SR: Polymerase chain reaction-based mRNA quantification using an internal standard: Analysis of oncogene expression. Methods Enzymol 218:446, 1993
15. Horikoshi T, Danenberg KD, Stadibauer TH, Volkenandt M, Shea LC, Aigner K, Gustavsson B, Leichman L, Frosing R, Ray M, Gibson NW, Spears CP, Danenberg PV: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52:108, 1992
16. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate, J Clin Invest 97:73, 1996
17. Pui CH, Evans WE: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499, 1998
18. Chadefaux B, Rethore MO, Raoul O, Ceballos I, Poissonnier M, Gilgenkranz S, Allard D: Cystathionine beta synthase: Gene dosage effect in trisomy 21. Biochem Biophys Res Commun 128:40, 1985
19. Peeters MA, Megarbane A, Cattaneo F, Rethore MO, Lejeune J: Differences in purine metabolism in patients with Down's syndrome. J Intellect Disabil Res 37:491, 1993 (part 6)
20. Patterson D, Graw S, Jones C: Demonstration, by somatic cell genetics, of coordinate regulation of genes for two enzymes of purine synthesis assigned to human chromosome 21. Proc Natl Acad Sci USA 78:405, 1981
21. Garre ML, Relling MV, Kalwinsky D, Dodge R, Crom WR, Abromowitch M, Pui CH, Evans WE: Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 111:506, 1987
22. Moscow JA, Connolly T, Myers TG, Cheng CC, Paull K, Cowan KH: Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines. Int J Cancer 72:184, 1997
23. Wong SC, Proefke SA, Bhushan A, Matherly LH: Mutations of the reduced folate carrier in transport impaired CCRF-CEM cells. Proc Annu Meet Am Assoc Cancer Res 38:1086a, 1997 (abstr)
24. Brigle KE, Spinella MJ, Sierra EE, Goldman ID: Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem 270:22974, 1995
25. Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, Barredo JC, Pui C-H, Relling MV, Evans WE: Differences in folylpoly-glutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 52:155, 1997
26. Longo GS, Gorlick R, Tong WP, Lin S, Steinherz P, Bertino JR: Gamma-glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res 9:259, 1997
27. Garrow TA, Admon A, Shane B: Expression cloning of a human cDNA encoding folylpoly (gamma-glutamate) synthetase and determination of its primary structure. Proc Natl Acad Sci USA 89:9151, 1992
28. Yao R: Studies of gamma-glutamyl hydrolase: Human tissue distribution and chromosome location, in Pfleiderer H, Rokos H (eds): Chemistry and Biology of Pteridines and Folates. Berlin, Germany, Blackwell, 1997, p 475
29. Spinella MJ, Brigle KE, Freemantle SJ, Sierra EE, Goldman ID: Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects. Biochem Pharmacol 52:703, 1996
30. Sierra EE, Spinella MJ, Brigle KE, Goldman ID: Evidence for a folate/antifolate influx process with optimal activity at low pH in an L1210 leukemia cell line lacking reduced folate carrier function. Proc Annu Meet Am Assoc Cancer Res 37:2609a, 1996 (abstr)
31. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499, 1998